Company intelligence / Profile preview

Breathe Biologics

United States

Ownership: Private
Development stage: Other

Overview

JadiCell™ (allogeneic umbilical cord-derived mesenchymal stem cells) has an active IND (#28508) for safety and efficacy in moderate-to-severe COPD; preclinical data show reduced lung injury and inflammation in emphysema models, outperforming bone marrow and adipose-derived MSCs.

Therapeutic areas: Pulmonology
Modalities: Mesenchymal stem cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Breathe Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Breathe Biologics.

Explore the full profile